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Research on Ethical Issues in Human Studies
NIH invites research grant applications to investigate
ethical issues in research using human subjects. The
Code of Federal Regulations (45 CFR, Part 46) pro-
vides a regulatory framework that all NIH-supported
researchers must follow. However, recent develop-
ments in biomedical and behavioral research—
including the rapid growth of new interventions and
technologies (e.g., stem cells, genetics research),
increasing involvement of foreign populations in clin-
ical research, and concerns about financial conflicts of
interest among researchers—challenge investigators’
abilities to interpret and apply the regulations. Other
situations (e.g., research with vulnerable populations,
the use of data banks or archives, research on stigma-
tizing diseases or conditions) may present difficulties
for identifying strategies, procedures, and/or tech-
niques that will enhance and ensure the ethical
involvement of human participants in research. 
The purpose of this PA is to support empirical
research addressing the ethical challenges of involv-
ing human participants in research in order to
inform and optimize protections for human partici-
pation in research. Examples of the types of topics
that would be appropriate for applications submitted
under this announcement include, but are not limit-
ed to, the following:
Minimizing Risks in Human Research
1) Assess how features of the research and
research setting affect evaluations of risks versus
potential benefits of different types of research for
investigators, institutional review board (IRB) mem-
bers, and potential participants, groups, and com-
munities. Examples of features of the research or
research setting may include characteristics of the
participants (e.g., age, health status and stage of dis-
ease, ethnic/cultural background, cognitive capacity,
social status, gender, incarceration), aspects of the
condition/disease (e.g., prevalence, severity,
chronicity, degree of disability), and the nation or
culture in which the study will take place.
2) Identify potential social, psychological,
and/or economic harms (e.g., stigma, discrimina-
tion, personal distress, loss of insurance coverage,
loss of employment) that may be associated with
recruitment, participation, or self-determined or
study-determined withdrawal from research.
Evaluate strategies or procedures for minimizing
these harms in regard to individuals’, groups’, com-
munities’, and populations’ willingness to participate
in different types of research.
3) Assess the conditions and assumptions under
which IRB evaluation of risk versus potential bene-
fits is similar to or different from the evaluation of
risks versus potential benefits by individuals, groups,
communities, and populations.
4) Assess the impact of obtaining a certificate of
confidentiality on perceptions of IRB members
and/or participants in terms of evaluation of risks,
understanding of the research, and/or understanding
of the rights to privacy.
5) Identify and evaluate strategies for protecting
and minimizing disclosure of private information
when identifiable data are collected via the Internet,
preserved for secondary analysis (e.g., in a tissue or
gene bank, data archive, warehouse), and/or collect-
ed about third parties in research (e.g., network
studies).
Issues in Informed Consent
1) Determine how features of the informed
consent process affect participants’ comprehension
and/or willingness to participate in research.
Examples of these features include a) variations in
the style of presentation (e.g., oral, written, graphic,
video); b) readability, complexity, and/or format of
the consent document; c) characteristics of the partic-
ipants (e.g., language preference, age, health status,
education, cultural/ethnic background, personal
motivations, cognitive capacity); and d) contextual
features or circumstances in which informed consent
takes place (e.g., characteristics of the research staff,
location such as research hospital versus private office
versus home, presence/involvement of family mem-
bers, presence/involvement of patient advocates). 
2) Evaluate different methods and identify best-
practice strategies for consulting with communities in
the United States and/or other countries regarding
comprehension, willingness to participate, and/or
willingness to continue with research at the individ-
ual, group, community, and/or population level.
3) Assess how recontacting participants to
obtain informed consent for additional uses of their
data affects participant comprehension, willingness
to participate, and sense of coercion.
4) Identify and evaluate strategies, procedures,
and/or techniques for improving comprehension of
research by individuals, groups, communities,
and/or populations at the time of initial consent,
during, and/or after completion of the study. Also,
determine how these strategies may differ depending
on age, health status, ethnic/cultural background,
cognitive capacity, social status, and/or gender of the
target audience.
5) Assess how participants’ willingness to partic-
ipate versus sense of coercion, may be affected by use
of different types of incentives, remuneration,
and/or provision of medical care; different features
of the research setting (e.g., personal physician as
recruiter and/or researcher, private funding versus
federal funding); and characteristics of the partici-
pants (e.g., health status, age, ethnic/cultural back-
ground, education, gender).
6) Assess the impact of communicating or not
communicating individual test results, study
progress, and/or study results on participants’ will-
ingness to continue with the protocol and/or partici-
pate in research again.
Oversight of Research and Research Data
1) Identify and evaluate strategies to improve
the oversight of human participants protection by
IRBs, data and safety monitoring boards (DSMB),
conflict of interest (COI) committees, etc. Examples
may include a) develop and evaluate best-practice
outcome measures for decision making about the
acceptability of research protocols; b) assess the con-
sistency of protocol review decisions within DSMBs,
IRBs, or COI committees; c) assess the impact of
conflicts of interest among members of oversight
committees on decision making about the accept-
ability of research protocols, interpretations of
adverse events, and/or perceptions of “independence
of review” by the research community; and d) assess
the impact of disclosing varying degrees of financial
conflicts of interest involving the principal investiga-
tor, members of oversight committees, sponsor,
institution, etc. on research participant willingness
to participate and/or continue with research, and/or
participant understanding of the research.
2) Compare and evaluate different methods and
strategies for identifying, reporting, and handling
adverse events based on the perspectives of individ-
ual participants, institutions, DSMBs, and/or IRBs.
This PA will use the NIH R01 award mecha-
nism and Just in Time concepts. It will also use the
modular as well as the nonmodular budgeting for-
mats (see http://grants.nih.gov/grants/funding/
modular/modular.htm). Specifically, if you are sub-
mitting an application with direct costs in each year
of $250,000 or less, use the modular format.
Otherwise follow the instructions for nonmodular
research grant applications. 
Applications must be prepared using the PHS
398 research grant application instructions and
forms (rev. 5/2001). The PHS 398 is available at
http://grants.nih.gov/grants/funding/phs398/phs398.
html in an interactive format. Complete information
on this PA is available at http://grants1.nih.gov/
grants/guide/pa-files/PA-02-103.html. To assist in
identifying which NIH institute/office most closely
matches your research topic, the following website
provides additional information about institute- and
office-specific research interests that will be support-
ed by this PA: http://grants.nih.gov/grants/
funding/ethics_contacts.htm.
Contact: Della M. Hann, Office of Extramural
Research, NIH, Building 1, Room 152, Bethesda,
MD 20892 USA, 301-402-2725, fax: 301-402-
3469, e-mail: hannd@od.nih.gov. Reference: PA
No. PA-02-103
Environmentally Induced Cardiovascular
Malformations
The NIEHS invites applications to study environ-
mental agents that cause cardiovascular malforma-
tions (CVMs). This PA is intended to stimulate
research to characterize environmental agents that
cause alterations in the development of the cardio-
vascular system and thereby lead to CVMs, and to
investigate the cellular and molecular mechanisms
involved in the development of these CVMs. The
use of mammalian and nonmammalian animal mod-
els, including transgenic and gene knockout animal
models, and of state-of-the-art molecular biology
techniques such as genomics and proteomics is
encouraged, as well as collaborations between envi-
ronmental health scientists and developmental biolo-
gists, to develop research programs to address the
high rate of CVMs.
CVMs are the most common type of birth
defect among live births in the United States, occur-
ring in approximately 0.8% of live births. The most
common types of CVMs include atrial or ventricular
septal defects, transposition of the great vessels, per-
sistent truncus arteriosus, teratology of Fallot, and
coarctations. Despite the importance of these in
malformations, in terms both of human suffering
and cost to the health care system, the causes of most
cases of CVMs are not known. 
Etiologic factors that have been identified
include genetics, maternal diseases such as diabetes,
certain drugs such as phenytoin and cocaine, and
dietary factors such as folic acid deficiency, vitamin
A excess, and copper deficiency. In addition, certain
environmental chemicals have been shown to be
associated with CVMs. For instance, in the
Baltimore–Washington Infant Study, a large epi-
demiologic study of cardiac malformations, exposure
to such environmental factors as paints, solvents,
degreasers, and pesticides was associated with
increased CVMs. 
Epidemiologic studies have also reported CVM
associations with air pollutants (ozone and carbon
monoxide) and trichloroethylene (TCE). In addi-
tion, environmental contaminants such as TCE, bis-
diamine, and dioxin have been shown to be cardiac
teratogens in animal studies.
Despite the evidence for an environmental role in
CVMs, the list of environmental agents tested for ter-
atogenic effects on the heart is limited, and relatively
little research has been done on the cellular and mole-
cular basis of the teratogenic effects of environmental
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agents or on the possible interactions between envi-
ronmental exposures and other factors such as diet and
genetics. Recent advances in genomic and molecular
biology technology and in the understanding of the
development of the fetal heart make this an opportune
time to initiate such studies.
Specific areas of interest to the NIEHS
include, but are not limited to, the following: 1)
characterization of new potential environmental
cardioteratogens that would include the types of
CVMs induced, dose–response evaluation, identifi-
cation of specific windows of vulnerability to the
agent, and development of preliminary data for fur-
ther mechanistic studies; 2) use of forward and
reverse mutagenesis studies in model organisms to
determine the genes altered by specific cardiovascu-
lar developmental toxicants and the relationship of
the altered gene activity to dysmorphogenesis; 3)
characterization of global gene expression profiles
in the developing heart of model organisms associ-
ated with the normal range of development and
after a developmentally toxic exposure (the rela-
tionship between the changes in gene expression
and the developmental lesion should be assessed);
4) use of genomic and/or proteomic profiling to
determine how well data on toxicant-induced mal-
formations can be extrapolated across species; 5)
identification and evaluation of specific signal
transduction pathways and the associated genetic
regulatory circuits that might be sites of action of
developmental cardiovascular toxicants (the causal
relationships between exposure and the CVMs
should be developed); and 6) determination of the
potential for interactions between exposures to
environmental agents and genetic susceptibility
that increase the risk for cardiovascular develop-
mental toxicity.
This PA will use the NIH R21 and R01 award
mechanism(s). Applications must be prepared using
the PHS 398 research grant application instruc-
tions and forms (rev. 5/2001). The PHS 398 is
available at http://grants.nih.gov/grants/funding/
phs398/phs398.html in an interactive format.
Applications submitted in response to this PA will
be accepted at the standard application deadlines,
which are indicated in the PHS 398 application kit.
Complete information on this PA is available at
http://grants.nih.gov/grants/guide/pa-files/
PA-02093.html.
Contact: J. Patrick Mastin, Scientific Program
Administrator, Organs and Systems Toxicology
Branch, Division of Extramural Research and
Training, NIEHS, PO Box 12233, EC-23, 111
T.W. Alexander Drive, Research Triangle Park, NC
27709 USA, 919-541-3289, fax: 919-541-5064, e-
mail: mastin@niehs.nih.gov. Reference: PA No. PA-
02-093
The Role of Gene–Environment Interactions
Underlying the Health Disparity of Premature
Birth
The National Institute of Child Health and Human
Development (NICHD), the National Institute of
Nursing Research (NINR), and the NIEHS are seek-
ing research grant applications on the role of
gene–environment interactions underlying the health
disparity of premature birth in the United States.
The major objective of this PA is to determine the
role of gene–environment interactions and genetic
diversity in the health disparity of premature birth.
This PA specifically addresses the need to better
understand how adverse societal, behavioral, and
environmental conditions alter gene expression and
interact with diverse genetic backgrounds to increase
a woman’s susceptibility for premature birth in high-
risk racial and ethnic groups in the United States.
Furthermore, the PA addresses the need for the iden-
tification and functional characterization of genetic
markers that increase the risk of premature birth
among these high-risk populations. Multidisciplinary
applications linking biomedical scientists with social
and behavioral scientists are highly encouraged.
This PA seeks research projects focused on one
or more of the following goals: 
1) Determine changes in gene or protein expres-
sion under adverse societal, behavioral, or environ-
mental conditions to identify candidate genes or
their corresponding proteins that may be involved in
increasing a woman’s susceptibility for premature
delivery in high-risk racial and ethnic populations in
the United States. Examples include, but are not
limited to, studies utilizing gene or protein expres-
sion profiling by high-throughput platforms, such as
DNA arrays, protein arrays, and protein
capture/SELDI-TOF mass spectrometry.
2) Determine the functional relevance of an
identified gene or protein for increasing a woman’s
susceptibility for premature delivery under adverse
societal, behavioral, or environmental conditions in
high-risk racial and ethnic populations in the United
States. Examples include, but are not limited to,
studies elucidating the function or mechanism of
action of an identified gene or protein in precipitat-
ing premature delivery.
3) Determine genomic differences that serve as
potential candidate markers for increasing a
woman’s susceptibility for premature delivery under
adverse societal, behavioral, or environmental condi-
tions in high-risk racial and ethnic populations in
the United States. Examples include, but are not
limited to, linkage studies using high-throughput
genotyping platforms to uncover genomic differ-
ences, such as sequence repeats and multiple or sin-
gle nucleotide polymorphisms.
4) Determine the functional relevance of can-
didate genomic markers associated with an
increased risk for premature birth in high-risk racial
and ethnic populations in the United States.
Examples include, but are not limited to, studies
that determine the functional consequence of these
markers as it relates to gene expression, function, or
regulation.
Applicants are encouraged to consider the com-
plexity of issues surrounding the meaning and assess-
ment of race and ethnicity, because an individual’s
identification with a particular racial or ethnic group
may involve not only an individual’s genetic back-
ground but also his or her cultural and geographical
identity. As appropriate for their particular propos-
als, applicants should consider the degree of genomic
heterogeneity within racial and ethnic populations
and that genetic differences may not apply broadly
to a specific race or ethnic group, and should consid-
er the new Office of Management and Budget
(OMB) directives on classifying race and ethnicity.
NIH policy on reporting race and ethnicity data
based on OMB directives is available at http://
grants.nih.gov/grants/guide/notice-files/
NOT-OD-01-053.html.
Because the NIEHS has expanded its research
agenda through the Environmental Genome Project,
the NIEHS is particularly interested in applications
that examine the complex interplay of genes and the
environment. The understanding of the critical role
of genetic susceptibility and sensitivity to environ-
mental exposures will lead to more effective disease
prevention and improved public health.
This PA will use the NIH research project grant
(R01) award mechanism. Applications must be pre-
pared using the PHS 398 research grant application
instructions and forms (rev. 5/2001). The PHS 398
is available at http://grants.nih.gov/grants/funding/
phs398/phs398.html in an interactive format.
Applications submitted in response to this PA will be
accepted at the standard application deadlines indi-
cated in the PHS 398 application kit. Complete
information on this PA is available at http://
grants.nih.gov/grants/guide/pa-files/
PA-02-102.html.
Contact: John V. Ilekis, Pregnancy and
Perinatology Branch, NICHD, 6100 Executive
Boulevard, Room 4B03, MSC 7510, Bethesda, MD
20892-7510 USA, 301-435-6895, fax: 301-496-
3790, e-mail: ilekisj@mail.nih.gov; Yvonne Bryan,
Division of Extramural Activities, NINR, 45 Center
Drive, Room 3AN-12, MSC 6300, Bethesda, MD
20892-6300 USA, 301-594-6908, fax: 301-480-
8260, e-mail: yvonne_bryan@nih.gov; Kimberly
Gray Kamins, Chemical Exposures and Molecular
Biology Branch, NIEHS, PO Box 12233, EC-21,
111 T.W. Alexander Drive, Research Triangle Park,
NC 27709 USA, 919-541-0293, fax: 919-316-
4606, e-mail: gray6@niehs.nih.gov. Reference: PA
No. PA-02-102
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